In this issue of JNO , Drs. Deborah I. Friedman and Mark L. Moster discuss the following 4 articles: Al Kasab S, Almallouhi E, Shu L, Kicielinski KP, Salehi Omran S, Liebeskind DS, Zubair AS, Vedovati MC, Paciaroni M, Antonenko K, Heldner MR, de Havenon A, Henninger N, Yaghi S. Outcomes and recurrence rates among patients with provoked and cryptogenic cerebral venous thrombosis: analysis of the ACTION CVT. Neurol Clin Pract. 2025
15:e200381 [Epub ahead of print].Kwon YN, Kim B, Kim JS, Park KS, Seo DY, Kim H, Lee EJ, Lim YM, Ju H, Chung YH, Min JH, Nam TS, Kim S, Sohn E, Shin KJ, Seok JM, Kim S, Bae JS, Lee S, Oh SI, Jung YJ, Park J, Kim SH, Kim KH, Kim HJ, Jung JH, Kim SJ, Kim SW, Jang MJ, Sung JJ, Waters P, Shin HY, Kim SM. Time to treat first acute attack of myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol. 2024
81:1073-1084.Akosman S, Li R, Asahi M, Kwon B, Dossantos J, Tavakoli M, Chen JJ. Trends in plasma exchange use in optic neuritis hospitalizations in the United States. Ophthalmology. 2024
131:1207-1214.Chou CC, Pan SY, Sheen YJ, Lin JF, Lin CH, Lin HJ, Wang IJ, Weng CH. Association between semaglutide and non-arteritic anterior ischemic optic neuropathy: a multinational population-based real-world study. Ophthalmology. 2024:S0161-6420(24)00685-7 [Epub ahead of print].